• Jacobio forecast net profit of at least RMB 600 million for H1 2026, versus a net loss of RMB 58.99 million a year earlier.
• Guidance implies the first interim profit for the group, driven by a sharp revenue increase.
• Key contributors included licensing income from AstraZeneca for ex-China rights to JAB-23E73, a pan-KRAS program.
• Additional revenue came from out-licensing and services with Shanghai Allist tied to glecirasib and sitneprotafib in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12279079), on August 10, 2026, and is solely responsible for the information contained therein.